Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Recently, two studies have claimed that cholesterol lowering drugs, particularly statins, protect against age related maculopathy. 1 2 The end stage of this progressive retinal disorder is the commonest cause of untreatable blindness in elderly people in Western societies, and its prevalence is expected to rise with the ageing of the population.Thus, preventing this disorder would have an enormous public health impact.3 The above mentioned studies used interview data on drug use and had a low statistical power.We therefore tested the hypothesis that cholesterol lowering drugs protect against age related maculopathy in a large cohort study with cumulative exposure measured. Participants, methods, and resultsThis investigation was part of the Rotterdam study, a population based cohort study of people aged 55 years and more.After the baseline phase from 1990 to 1993, two follow up examinations were performed at mean intervals of 2 and 6.5 years.Of all the subjects at risk of age related maculopathy, 4822 (83%) participated at follow up.A diagnosis of age related maculopathy was based on stereoscopic colour fundus transparencies graded according to the international classification system.4 The incidence of the disorder was defined as the development of soft distinct drusen with pigmentary irregularities, indistinct drusen, or the end stages of atrophic or neovascular age related macular degeneration.A register of prescriptions filled by local pharmacies provided continuous data on use of cholesterol lowering drugs.These data were available for 99% of the cohort from 1 January 1991 onwards.We used Cox proportional hazards regression analysis to calculate hazard ratios, with age in days as the time axis to ensure optimal controlling for age.Cumulative exposure to drugs was represented as a time dependent covariate and was analysed both as a dichotomous and a categorical variable.The model compared each incident case of age related maculopathy with all subjects in the cohort who were alive and free of the disorder at the age when the case of maculopathy was diagnosed.5 During 26 781 person years of follow up, 457 patients used cholesterol lowering drugs for one or more days, and 419 cases of incident age related maculopathy were observed.Use of cholesterol lowering drugs at any time, defined as a binary variable, was not associated with the incidence of age related maculopathy (hazard ratio 1.0 (95% confidence interval 0.7 to 1.5)).Compared with patients who had never used cholesterol lowering drugs, cumulative exposure for less than one month, for one month to a year, or for more than a year did not have a protective effect on the risk of maculopathy (see table ).Additional adjustment for body mass index, hypertension, smoking, and peripheral arterial disease (ankle:arm index < 0.9) did not change the association.When we performed the same analysis with progression of age related maculopathy as the outcome variable, we obtained the same results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926 · cited 1×
“This investigation was part of the Rotterdam study, a population based cohort study of people aged 55 years and more. After the baseline phase from 1990 to 1993, two follow up examinations were performed at mean intervals of 2 and 6.5 years. Of all the subjects at risk of age related maculopathy, 4822 (83%) participat…”
MethodInfluentialSelf-citationNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Self-citation
Cited by
The Rotterdam Study: objectives and design update
Hofman, A., Breteler, M. M. B., van Duijn, C. M., Krestin, G. P., Pols, H. A., Stricker, B. H. C., Tiemeier, H., Uitterlinden, A. G., Vingerling, J. R., & Witteman, J. C. M. (2007) · European Journal of Epidemiology · doi:10.1007/s10654-007-9199-x · Cited by 1,395
Self-citationThe epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
The Rotterdam Study: 2012 objectives and design update
Hofman, A., van Duijn, C. M., Franco, O. H., Ikram, M. A., Janssen, H. L. A., Klaver, C. C. W., Kuipers, E. J., Nijsten, T. E. C., Stricker, B. H. C., Tiemeier, H., et al. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9610-5 · Cited by 289
Self-citationA new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
The Rotterdam Study: 2010 objectives and design update
Hofman, A., Breteler, M. M. B., van Duijn, C. M., Janssen, H. L. A., Krestin, G. P., Kuipers, E. J., Stricker, B. H. C., Tiemeier, H., Uitterlinden, A. G., Vingerling, J. R., et al. (2009) · European Journal of Epidemiology · doi:10.1007/s10654-009-9386-z · Cited by 244
Self-citation
Metadata
- Authors
- van Leeuwen, R., Vingerling, J. R., Hofman, A., de Jong, P. T. V. M., & Stricker, B. H. C.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2003-02-01
- Volume
- 326
- Issue
- 7383
- Pages
- 255-256
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2148959041
- Cited by
- 81
- References
- 2
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.